Nemolizumab delivered long-term symptom relief in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, according to Phase II data presented at PeDRA 2026.

The findings, carried by Yahoo Finance, mark one of the first structured looks at the interleukin-31 receptor antagonist in a pediatric cohort this young. The trial population spanned ages 2 through 11, all with moderate-to-severe disease.

What does the data show?

The presentation, titled "PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis," reports sustained symptom improvement over the long-term treatment window.

The source report does not publish the full endpoint table. Derm Field will update this story with exact effect sizes, EASI or itch-score figures, and safety data once the full presentation is available.

Why the age range matters

Moderate-to-severe atopic dermatitis in children aged 2 to 11 has limited approved biologic options. A long-term safety and efficacy signal in this cohort could widen treatment choices for pediatric dermatologists.

Full Phase II details, including dosing and duration of follow-up, are expected as the PeDRA 2026 presentation circulates.